KGP207

KGP207 is a small-molecule inhibitor of cathepsin L (CTSL) and cathepsin K (CTSK). Developed by researchers at Baylor University, KGP207 is a benzophenone thiosemicarbazone derivative designed to target lysosomal cysteine proteases. In preclinical studies, KGP207 has demonstrated the ability to prevent the differentiation of M0 macrophages into pro-tumorigenic M2 macrophages, reduce macrophage motility and invasion, and impair macrophage-stimulated invasion of breast cancer cells. By inhibiting cathepsin L and K, KGP207 represents a potential therapeutic strategy for treating cancers characterized by high macrophage infiltration and metastatic potential, such as breast cancer.